NEW YORK (360Dx) – Quidel said today that it has closed its previously announced acquisition of Alere's Triage MeterPro cardiovascular and toxicology business and its B-type natriuretic peptide (BNP) assay business.
The total cash consideration for the deal, which included real estate in San Diego for the Triage facilities, was $680 million. This consisted of a $400 million purchase price for the Triage business and $280 million in "deferred consideration" for the BNP business.
Quidel President and CEO Douglas Bryant said in a statement that the strategic acquisition adds "an extensive cardiovascular and toxicology [point-of-care] offering to our innovative medical diagnostics portfolio, as well as direct commercial responsibility for the BNP assay business globally."
Quidel has said that the Triage MeterPro installed base of cardiovascular and toxicology instruments is complementary to its installed base of Sofia instruments, and would provide it with entry into new and fast-growing point-of-care testing areas.
The Alere assay for detecting B-type natriuretic peptide, a hormone produced by the heart, runs on Beckman Coulter analyzers.
Quidel's announcement today comes after Abbott completed the acquisition of Alere earlier this week.